We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Loss-of-Imprinting Test Predicts Risk of Colon Cancer

By Biotechdaily staff writers
Posted on 28 Mar 2003
A recent study describes a new blood test for determining the risk for colon cancer, based on detection of a type of gene silencing known as loss of imprinting (LOI). More...
The study was published in the March 14, 2003, issue of Science.

Imprinting means that the copy of a gene inherited from one parent is active while the same gene from the other parent is inactive, or silent. For some genes the active gene is the maternal copy and for others it is the paternal. Prior work had shown that LOI in the growth-promoting gene IGF2 (insulin-like growth factor) is one of the first genetic defects that occurs in up to 40% of colon cancers. In the current study, investigators from Johns Hopkins University (Baltimore, MD, USA; www.jhu.edu) found IGF2-related LOI present in blood samples as well as in colon tissue.

DNA analysis of blood samples from 172 individuals after colonoscopy revealed that 25 with various family and personal histories of colon cancer and polyps expressed LOI in their blood. Those with a family history of colon cancer were more than five times more likely to have LOI markers than those with no such family history. Individuals with polyps were nearly three and a half times more likely to have LOI markers present in the blood, while individuals with a personal history of colon cancer were nearly 22 times more likely to have LOI markers.

"We hope these findings will have the ability to identify people at increased risk for colon cancer, follow them closely, and prevent disease or at least catch it early, similar to the approach doctors use in identifying patients at risk of heart disease,” said Dr. Andrew P. Feinberg, professor of medicine at the Kimmel Cancer Center at Johns Hopkins University.



Related Links:
Johns Hopkins University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.